Document is current
Any future updates will be listed below
-
Authors
-
Funding
Funding for this research was provided by:
Daiichi Sankyo Co., Ltd., Japan (NA)
- License Information
-
More Information
Article History
Received: 29 August 2025
Accepted: 6 December 2025
First Online: 31 January 2026
Declarations
:
: JT is an adviser for Daiichi Sankyo Co., Ltd., AstraZeneca K.K., Gilead Sciences, Inc., Pfizer Japan Inc., and Seegene Inc. and has received honoraria from Daiichi Sankyo Co., Ltd., Eli Lilly Japan K.K., Kyowa Kirin Co., Ltd., Taiho Pharmaceutical Co., Ltd., Eisai Co., Ltd., AstraZeneca K.K., Gilead Sciences, Inc., Pfizer Japan Inc., Chugai Pharmaceutical Co., Ltd., and MSD K.K. KN and AT are employees of Daiichi Sankyo Co. Ltd., Japan.
: According to the ordinance of the Ministry of Health, Labour and Welfare No. 171, neither acquisition of informed consent from patients nor ethics committee approval at the participating sites was required for this PMS study. The study protocol was reviewed by the Pharmaceuticals and Medical Devices Agency in Japan.
